The Nasus Pharma Ltd. (NSRX) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on the NYSE American. Nasus Pharma files reports with the U.S. Securities and Exchange Commission that include current information on its clinical programs, financial condition, governance, and material agreements.
Nasus Pharma submits current reports on Form 6-K, which have covered topics such as condensed unaudited interim financial statements and management’s discussion and analysis for specified periods, leadership appointments, clinical trial milestones, and collaboration agreements. For example, Form 6-K reports have described the appointment of an Executive Vice President and Chief Financial Officer, the initiation of a Phase 2 clinical study of NS002 with first participant dosed, and expanded agreements with Aptar France S.A.S. and AptarGroup, Inc. to support the intranasal epinephrine program.
Filings also document capital markets events, including the registration and completion of Nasus Pharma’s initial public offering on Form F-1 and subsequent updates on the partial exercise of the underwriters’ over-allotment option. These disclosures outline the company’s stated use of proceeds, such as funding further development of its intranasal epinephrine program and general corporate purposes, and provide detail on underwriting arrangements.
As a foreign private issuer, Nasus Pharma is required to file an annual report on Form 20-F, and it supplements this with periodic Form 6-K submissions when it releases press statements or corporate presentations that are material to investors. Some 6-K filings incorporate press releases, such as the CEO’s letter to shareholders or news of regulatory clearances, directly as exhibits.
On this page, users can review Nasus Pharma’s SEC filings as they are made available through the EDGAR system. Stock Titan enhances access by pairing filings with AI-powered summaries that help explain key sections, highlight clinical and financial themes, and make lengthy documents such as financial statements and management analyses easier to understand. Investors can quickly identify filings related to clinical progress of NS002, leadership and governance changes, capital raising activities, and significant collaboration agreements.
Nasus Pharma Ltd (NSRX), a clinical-stage biopharmaceutical company focused on innovative intranasal therapies, announced that its Chief Financial Officer, Eyal Rubin, has resigned, effective September 18, 2026. The company states that his resignation is not related to any disagreement regarding operations, policies, or practices. Rubin will remain through the effective date to support a seamless transition. Oren Elmaliach, currently Director of Finance and with Nasus since its inception, has been appointed Interim Chief Financial Officer. Elmaliach is a certified public accountant with over 15 years of financial experience, including work with public and private life sciences companies and within the U.S. public markets and reporting environment. The 6-K (excluding parts of the press release) is incorporated by reference into Nasus Pharma’s Form S-8 registration statement.
Nasus Pharma Ltd (NSRX) has filed a post-effective amendment to its Form F-1 covering the resale by selling shareholders of up to 5,121,308 Ordinary Shares. This includes 2,425,883 existing shares and 2,695,425 shares issuable upon exercise of private-placement warrants.
No shares are being sold by Nasus itself, and the company will not receive proceeds from any resale of shares, only from cash paid if the warrants with a $6.53 exercise price are exercised. Ordinary shares outstanding were 11,710,808 as of June 30, 2026, or 14,406,233 assuming full warrant exercise; this is a baseline ownership figure, not the amount being offered. Nasus remains a clinical-stage intranasal drug developer, with lead candidate NS002 (intranasal epinephrine) advancing through Phase 2 toward planned Phase 3 and IND filing, and NS003 (intranasal ondansetron) moving toward first-in-human studies.
Nasus Pharma Ltd. reported a larger first-half net loss as it accelerated clinical development while strengthening its balance sheet. For the six months ended June 30, 2026, net loss was $5.9 million compared with $1.3 million a year earlier, driven by sharply higher operating expenses. Research and development rose to $2.6 million from $0.3 million, mainly for NS002 epinephrine intranasal programs, while general and administrative expenses increased to $3.4 million from $0.5 million due to public-company and consulting costs and bonuses.
Liquidity improved following a February 2026 private placement of Ordinary Shares and warrants that generated $15.0 million in gross proceeds. Cash, cash equivalents, restricted cash and short-term deposits were $11.9 million at June 30, 2026 versus $4.3 million at December 31, 2025, and management currently expects funding to last through the second quarter of 2027, though it also states there is substantial doubt about the company’s ability to continue as a going concern without additional capital. Operationally, Nasus advanced NS002 with positive Phase 2 data and plans a pivotal study starting in the fourth quarter of 2026, and moved NS003 toward first-in-human testing, while appointing industry veteran Brendan O’Grady as Chief Executive Officer.
Balyasny Asset Management and affiliated entities report beneficial ownership of approximately 9.99% of Nasus Pharma Ltd. common stock. The position is held through Atlas Private Holdings (Cayman) Ltd., which directly holds 898,473 shares plus 271,437 shares issuable upon exercise of warrants, all subject to a Beneficial Ownership Limitation that blocks exercises above 9.99% of outstanding shares. The percentage is based on 11,710,808 shares outstanding as of March 27, 2026. The reporting persons have sole voting and dispositive power over the reported shares, and APHC is entitled to dividends and sale proceeds.
Nasus Pharma Ltd filed an insider report identifying Brendan P. O'Grady as both a director and an officer, with the officer title of Chief Executive Officer. The report does not list him as a ten percent owner and shows no insider share transactions in this filing.
Nasus Pharma Ltd disclosed that Dan Benjamin Teleman has ceased to serve as Chief Executive Officer and resigned as a director on the Board of Directors, effective July 22, 2026. As a result, he is no longer subject to Section 16 reporting obligations regarding Nasus Pharma securities.
Nasus Pharma Ltd. appointed Brendan P. O’Grady as Chief Executive Officer, effective July 27, 2026, following a mutual separation agreement with former CEO and director Dan Teleman, whose resignation was described as not stemming from any disagreement over operations, policies or practices.
The board also appointed Mr. O’Grady as a Class III director, with a term running until the 2028 annual general meeting, and approved a compensation package that still requires shareholder approval. He is expected to enter into the company’s standard indemnification and exemption agreement. Nasus highlighted Mr. O’Grady’s three decades of global pharma leadership and stated that he will focus on unlocking the commercial potential of lead intranasal epinephrine candidate NS002, advancing the pipeline and business development, and maximizing the Nasax intranasal technology platform. The company referenced plans to move NS002 toward a pivotal trial in the fourth quarter of 2026 with topline data in the first quarter of 2027 and cited a $2 billion anaphylaxis treatment market opportunity. An updated corporate presentation was also made available.
Nasus Pharma Ltd Chief Executive Officer and director Dan Benjamin Teleman reported an open-market purchase of 6,550 Ordinary Shares at $3.10 per share. Following this transaction, he directly owns 163,541 Ordinary Shares in total. This holding includes 30,696 Ordinary Shares and 132,845 additional Ordinary Shares that are issuable from share options exercisable within 60 days, highlighting a meaningful option-based exposure alongside his common share position.
Nasus Pharma Ltd. reported positive preclinical results for NS003, its intranasal powder formulation of ondansetron for chemotherapy- and surgery-related nausea and vomiting. In an animal study, NS003 showed a pharmacokinetic profile comparable to intravenous ondansetron, with similar time to maximum concentration and area under the curve.
A separate toxicology study found a favorable safety profile at four times the test dose with no adverse effects. Based on these results, Nasus plans to start a first-in-human pharmacokinetic study of NS003 in the third quarter of 2026 and then advance NS002, its intranasal epinephrine candidate for anaphylaxis, to a pivotal study in the fourth quarter of 2026.
Balyasny Asset Management and affiliated reporting persons state beneficial ownership of 1,169,910 shares of Nasus Pharma Ltd common stock, representing approximately 9.99% of the class. The percentage is calculated using 11,710,808 Shares outstanding as of March 27, 2026.
The filing clarifies that 1,169,910 shares include 271,437 shares issuable upon exercise of 898,473 Warrants subject to a Beneficial Ownership Limitation that prevents exercise resulting in ownership above 9.99%. The shares are held through Atlas Private Holdings (Cayman) Ltd and reported on behalf of that client.